Optimal utilisation of sulphonylureas in resource-constrained settings

Area of Science:

• Endocrinology
• Pharmacology
• Internal Medicine

Background:

• Sulphonylureas (SUs) are established oral anti-diabetic drugs (OADs) with over 60 years of clinical use.
• Despite familiarity, SUs are linked to adverse effects like weight gain and hypoglycemia, with cardiovascular effects debated.
• Newer anti-diabetic classes offer weight neutrality or loss and improved safety profiles but are more expensive and have unknown long-term effects.

Purpose of the Study:

• To evaluate the continued relevance of Sulphonylureas (SUs) in diabetes management.
• To compare the risks and benefits of SUs against newer anti-diabetic agents.
• To provide guidance on mitigating SU-associated adverse effects.

Main Methods:

• Review of existing literature on Sulphonylureas and newer anti-diabetic drug classes.
• Comparative analysis of efficacy, safety profiles (hypoglycemia, weight changes, cardiovascular events), cost, and long-term data.
• Assessment of clinical scenarios favoring SU use versus newer agents.

Main Results:

• Sulphonylureas are likely to remain in use, particularly in resource-limited settings, due to cost-effectiveness.
• Newer agents like DPP-IV inhibitors, GLP-1 analogues, and SGLT-2 inhibitors present advantages in weight and hypoglycemia profiles.
• Strategies to mitigate SU risks include selecting agents with lower adverse event potential and using the lowest effective dose.

Conclusions:

• Sulphonylureas will likely continue to be prescribed, necessitating careful management to minimize adverse effects.
• For high-risk patients or those where hypoglycemia has severe consequences, newer anti-diabetic agents may be a more appropriate choice.
• Balancing cost, efficacy, and safety is crucial in selecting anti-diabetic therapies, especially considering resource limitations.